Your browser is no longer supported. Please, upgrade your browser.
Settings
BCRX BioCryst Pharmaceuticals, Inc. daily Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.64 Insider Own0.20% Shs Outstand98.84M Perf Week5.68%
Market Cap514.96M Forward P/E- EPS next Y-0.81 Insider Trans-37.49% Shs Float97.31M Perf Month10.85%
Income-50.70M PEG- EPS next Q-0.15 Inst Own85.90% Short Float11.11% Perf Quarter-9.39%
Sales30.30M P/S17.00 EPS this Y-26.80% Inst Trans20.78% Short Ratio7.22 Perf Half Y-2.98%
Book/sh1.20 P/B4.34 EPS next Y-12.50% ROA-38.70% Target Price8.56 Perf Year-7.62%
Cash/sh1.63 P/C3.19 EPS next 5Y19.90% ROE-123.10% 52W Range3.95 - 9.25 Perf YTD-17.69%
Dividend- P/FCF- EPS past 5Y9.90% ROI-87.90% 52W High-43.68% Beta3.12
Dividend %- Quick Ratio2.50 Sales past 5Y6.10% Gross Margin88.60% 52W Low31.90% ATR0.28
Employees65 Current Ratio2.50 Sales Q/Q12.80% Oper. Margin- RSI (14)61.10 Volatility7.01% 5.70%
OptionableYes Debt/Eq0.54 EPS Q/Q-15.80% Profit Margin- Rel Volume2.17 Prev Close4.57
ShortableYes LT Debt/Eq0.21 EarningsNov 07 BMO Payout- Avg Volume1.50M Price5.21
Recom2.20 SMA2010.91% SMA508.43% SMA200-9.09% Volume3,231,308 Change14.00%
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Feb-08-16Downgrade Piper Jaffray Overweight → Neutral
Jan-06-16Upgrade Jefferies Hold → Buy
Nov-11-15Downgrade BofA/Merrill Neutral → Underperform
Oct-09-15Downgrade BofA/Merrill Buy → Neutral
Sep-09-15Initiated Jefferies Hold
Jun-30-15Upgrade BofA/Merrill Neutral → Buy $12 → $19
Apr-21-15Initiated FBR Capital Outperform $18
Apr-20-15Upgrade BofA/Merrill Underperform → Neutral $8 → $12
May-30-14Reiterated H.C. Wainwright Buy $21 → $24
Mar-04-14Reiterated MLV & Co Buy $9 → $15
Dec-07-17 01:01PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 7, 2017 Capital Cube
Dec-05-17 08:57AM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017 Capital Cube
Dec-04-17 11:16AM  BioCryst Pharmaceuticals, Inc. Value Analysis (NASDAQ:BCRX) : December 4, 2017 Capital Cube
Dec-01-17 07:12AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : December 1, 2017 Capital Cube
Nov-16-17 06:00AM  BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-14-17 02:12PM  Edited Transcript of BCRX earnings conference call or presentation 7-Nov-17 4:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 10:53AM  Does BioCryst Pharmaceuticals Incs (BCRX) Debt Level Pose A Serious Problem? Simply Wall St.
06:13AM  BioCryst reports 3Q loss Associated Press
06:00AM  BioCryst Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 09:23AM  Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers TheStreet.com
Nov-02-17 11:52AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 2, 2017 Capital Cube
Nov-01-17 06:00AM  BioCryst to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire
Oct-27-17 06:00AM  BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAIs 2017 Annual Scientific Meeting GlobeNewswire +6.25%
Oct-24-17 06:00AM  BioCryst to Announce Third Quarter 2017 Financial Results on November 7 GlobeNewswire
Oct-23-17 08:31AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : October 23, 2017 Capital Cube -8.96%
Oct-17-17 09:35AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 17, 2017 Capital Cube
Oct-04-17 06:00AM  BioCryst Announces RAPIVAB® (peramivir injection) and Galidesivir Presentations at IDWeek 2017 GlobeNewswire
Oct-03-17 10:54AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 3, 2017 Capital Cube
Sep-22-17 11:03AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : September 22, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Biocryst Pharmaceuticals ACCESSWIRE
Sep-21-17 02:35PM  BioCryst scores FDA approval on flu treatment for children American City Business Journals
12:17PM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017 Capital Cube
10:10AM  FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers TheStreet.com
09:55AM  Can BioCryst Turn Itself Around With This FDA Approval? 24/7 Wall St.
09:03AM  Have Investors Already Priced In BioCryst Pharmaceuticals Incs (BCRX) Growth? Simply Wall St.
06:00AM  BioCrysts RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication GlobeNewswire
Sep-15-17 12:00PM  BioCryst Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock GlobeNewswire
08:00AM  BioCryst Meeting with FDA to Design Phase III Trial for BCX7353 and PDUFA Review for RAPIVAB ACCESSWIRE
Sep-14-17 03:15PM  How BioCryst aims to use its $80M public offering American City Business Journals
Sep-12-17 09:00PM  BioCryst Pharmaceuticals Prices Public Offering of Common Stock GlobeNewswire -9.04%
10:50AM  BioCryst Pharmaceuticals Announces Secondary Offering 24/7 Wall St.
Sep-11-17 04:01PM  BioCryst Pharmaceuticals Commences Public Offering of Common Stock GlobeNewswire
Sep-05-17 10:35AM  BioCryst Pharma Sees Brief Surge on Mid-Stage Trial Win 24/7 Wall St.
06:00AM  BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE GlobeNewswire
Sep-04-17 02:00PM  BioCryst Announces Corporate Update Conference Call and Webcast GlobeNewswire
Sep-01-17 09:00AM  Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock? Zacks
Aug-23-17 06:00AM  BioCryst to Present at Three Upcoming Investor Conferences GlobeNewswire
Aug-12-17 09:00AM  Edited Transcript of BCRX earnings conference call or presentation 7-Aug-17 3:00pm GMT Thomson Reuters StreetEvents
Aug-07-17 11:57PM  BioCryst reports 2Q loss Associated Press -13.33%
06:00AM  BioCryst Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-02-17 06:00AM  BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks GlobeNewswire
Aug-01-17 05:48PM  BioCryst Pharmaceuticals, Inc. Value Analysis (NASDAQ:BCRX) : August 1, 2017 Capital Cube
Jul-24-17 02:21PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : July 24, 2017 Capital Cube
06:00AM  BioCryst to Announce Second Quarter 2017 Financial Results on August 7 GlobeNewswire
Jul-18-17 09:33AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : July 18, 2017 Capital Cube
Jul-13-17 03:35PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : July 13, 2017 Capital Cube
Jul-07-17 08:00AM  Today's Research Reports on Stocks to Watch: BioCryst Pharmaceuticals and Exact Sciences Accesswire
Jul-04-17 08:56AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : July 4, 2017 Capital Cube
Jul-03-17 02:56PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : July 3, 2017 Capital Cube +5.04%
Jun-21-17 08:04AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : June 21, 2017 Capital Cube
Jun-16-17 03:26PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : June 16, 2017 Capital Cube
Jun-15-17 08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on BioCryst Pharmaceuticals and TG Therapeutics Accesswire
Jun-14-17 09:55AM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube +5.84%
Jun-13-17 06:00AM  BioCryst to Present at the JMP Securities 2017 Life Sciences Conference GlobeNewswire
Jun-06-17 12:03PM  Down 24.6%, is BioCryst Pharmaceuticals Stock Now a Buy? Motley Fool
11:05AM  Flu therapy from RTP's BioCryst could be available for kids next season American City Business Journals
Jun-05-17 06:00AM  BioCryst Announces RAPIVAB® Pediatric sNDA Acceptance GlobeNewswire
May-31-17 06:00AM  BioCryst to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire -6.53%
May-30-17 07:30AM  Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals, Inc. GlobeNewswire
May-26-17 05:04PM  Why Zoe's Kitchen, Beazer Homes, and BioCryst Pharmaceuticals Slumped Today Motley Fool -14.26%
08:00AM  BioCryst and Aerie Pharmaceuticals' Shares Swell on Positive Study Results Accesswire
May-25-17 03:06PM  Why BioCryst Pharmaceuticals Stock Caught Fire Today Motley Fool +31.19%
02:55PM  Stocks rise for Aerie, BioCryst following positive trial results American City Business Journals
09:37AM  Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring TheStreet.com
08:00AM  BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial GlobeNewswire
May-18-17 11:54AM  Shire's swelling disorder drug moves closer to U.S. approval Reuters +5.58%
May-16-17 08:43AM  Implied Volatility Surging for BioCryst (BCRX) Stock Options Zacks
May-11-17 04:00PM  Edited Transcript of BCRX earnings conference call or presentation 4-May-17 3:00pm GMT Thomson Reuters StreetEvents
May-09-17 04:30PM  BioCryst to Present at the Bank of America Merrill Lynch 2017 Health Care Conference GlobeNewswire
May-05-17 08:00AM  Today's Research Reports on Biotech Stocks to Watch: BioCryst Pharmaceuticals and Keryx Biopharmaceuticals Accesswire
May-04-17 10:00AM  Investor Network: BioCryst Pharmaceuticals, Inc. to Host Earnings Call Accesswire -10.59%
06:20AM  BioCryst reports 1Q loss Associated Press
06:00AM  BioCryst Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-24-17 12:01PM  BioCryst to Announce First Quarter 2017 Financial Results May 4 GlobeNewswire
Apr-13-17 12:13PM  After announcing a $45M public offering, BioCryst to launch new trial American City Business Journals
Apr-12-17 06:45AM  BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks GlobeNewswire -5.68%
Apr-04-17 10:50AM  BioCryst to receive royalties from cancer treatment approved in Japan American City Business Journals
10:50AM  BioCryst to receive royalties from cancer treatment approved in Japan
Apr-03-17 12:55PM  Stocks of companies with Raleigh-Durham area HQ make a comeback in March at bizjournals.com
12:55PM  Stocks of companies with Raleigh-Durham area HQ make a comeback in March American City Business Journals
07:18AM  BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan GlobeNewswire
Mar-29-17 06:52AM  BioCryst to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-21-17 09:32AM  Biotech Premarket Movers: Esperion, Minerva and BioCryst -9.89%
Mar-20-17 01:29PM  Wait for the Pullback on BioCryst Pharmaceuticals TheStreet.com
01:29PM  Wait for the Pullback on BioCryst Pharmaceuticals
Mar-19-17 01:51PM  Don't Let Offerings Blindside Your Thesis Benzinga
01:51PM  Don't Let Offerings Blindside Your Thesis
Mar-17-17 05:01PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
09:58AM  Teva Launches Authorized Generic of Allergan's Minastrin
Mar-15-17 03:47PM  AstraZeneca's Cancer Drug Lynparza Positive in Phase III
10:36AM  BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue? Zacks
10:36AM  BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue?
06:13AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-14-17 09:28AM  Its time to vaccinate your investments against a deadly bird flu MarketWatch
09:28AM  Its time to vaccinate your investments against a deadly bird flu at MarketWatch
Mar-09-17 08:21PM  BioCryst Pharmaceuticals Prices Public Offering of Common Stock GlobeNewswire
10:07AM  Biotech Premarket Movers: Spectrum, BioCryst, Curis
Mar-08-17 04:58PM  The Reason Behind BioCryst Pharmaceuticals, Inc.'s 12% Pop Higher at Motley Fool +8.38%
04:01PM  BioCryst Pharmaceuticals Commences Public Offering of Common Stock GlobeNewswire
08:15AM  Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sheridan William PSenior VP - CMONov 13Sale4.7264,310303,54323,855Nov 15 04:09 PM
Cohen Fred EDirectorSep 18Option Exercise4.2754,250231,648173,660Sep 20 10:07 AM
Cohen Fred EDirectorSep 18Sale5.4254,250294,035119,410Sep 20 10:07 AM
STAAB THOMAS R IISenior Vice President and CFOMay 22Option Exercise4.737,75036,658149,210May 24 04:33 PM
STAAB THOMAS R IISenior Vice President and CFOMar 20Option Exercise3.783,25012,285144,710Mar 22 10:40 AM
STAAB THOMAS R IISenior Vice President and CFOMar 20Sale9.203,25029,900141,460Mar 22 10:40 AM
STAAB THOMAS R IISenior Vice President and CFOMar 16Option Exercise2.9736,455108,300153,768Mar 20 03:01 PM
STAAB THOMAS R IISenior Vice President and CFOMar 10Option Exercise3.783,25012,285120,563Mar 14 01:47 PM
STAAB THOMAS R IISenior Vice President and CFOMar 10Sale9.063,25029,445117,313Mar 14 01:47 PM
STAAB THOMAS R IISenior Vice President and CFOMar 08Option Exercise3.786,50024,570123,813Mar 10 04:19 PM
STAAB THOMAS R IISenior Vice President and CFOMar 08Sale8.436,50054,763117,313Mar 10 04:19 PM
STAAB THOMAS R IISenior Vice President and CFOMar 06Option Exercise3.783,25012,285120,563Mar 08 08:05 AM
STAAB THOMAS R IISenior Vice President and CFOMar 06Sale7.903,25025,675117,313Mar 08 08:05 AM
STAAB THOMAS R IISenior Vice President and CFODec 19Option Exercise3.783,25012,285127,437Dec 21 10:42 AM
STAAB THOMAS R IISenior Vice President and CFODec 19Sale7.453,25024,213124,187Dec 21 10:42 AM